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Background: Small hepatocellular carcinoma (SHCC) is a special type of hepatocellular carcinoma with the
maximum tumor diameter ≤ 3 cm and excellent long-term outcomes. However, the prognostic factors for SHCC
remain controversial. The purpose of this study is to clarify the predictive factors of SHCC.
Methods: The study population consisted of 458 patients underwent hepatectomy for single SHCC between
January 2006 and December 2008. Clinical data (included age, gender, virus infection, serum alfa-fetoprotein level,
cirrhosis, capsule, border), histopathologic features (included differentiation, morphology subtype, microvascular
invasion, tumor infiltrative lymphocytes (TIL), inflammatory injury grade and fibrosis stage of surrounding liver), were
evaluated to identify prognostic factors influencing SHCC patients’ survival and microvascular invasion.
Results: There were 384 males (83.8%) and 74 (16.2%) females with median ages of 52 years. The median progression-free
survival (PFS) and overall survival (OS) durations were 53 and 54 months, respectively. About 91.9% (n = 421) SHCC
were infected by Hepatitis B. One hundred forty-seven of the 446 (33.0%) patients with pre-operation serum AFP level
record had serum alfa-fetoprotein (AFP) level ≥ 200 ug/ml and 178 of the 280 (63.8%) patients with post-operation
serum AFP level record had AFP level ≥ 20 ug/ml. Liver cirrhosis was present in 411 cases (89.7%), while 434 (97.3%)
tumors had clear border, and 250 (55.6%) tumors were encapsulated.
MVI was identified in 83 patients (18.1%). In univariate analysis, a significant association between the presence of MVI
and shortened PFS and OS was found (p = 0.012, 0.028, respectively). Histological differentiation had strong relationship
with MVI (p = 0.009), in terms of MVI was more easily presented in patients with worse histological differentiation. In
patients with MVI, worse survival was correlated with female patients, patients with G2 or G3 histological differentiation,
pre-operation serum AFP level ≥ 200 ug/ml or post-operation serum AFP level ≥ 20 ug/ml, and TIL ≥ 50/HPF.
Conclusions: MVI is an independent poorer prognostic factor for PFS and OS of single SHCC patients. Tumor
histological differentiation was closely related with MVI.
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Hepatocellular carcinoma (HCC) is the fifth most com-
mon malignancy and the third cause of cancer-associated
death worldwide, with the increase of incidence and
mortality every year [1]. Patients with solitary HCC up
to 3cm has been reported to be less aggressive and
characterized by excellent long-term outcomes after
surgical resection in several studies. The size cutoff of* Correspondence: ji.yuan@zs-hospital.sh.cn
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reproduction in any medium, provided the or3 cm has been first adopted to define SHCC in the
Pathological Classification of Liver Cancer in 1979 and
the latest edition of the Consensus of Diagnosis and
Treatment of Primary Liver Cancer in 2009 in China
followed the definition [2]. In addition to tumor size,
worse histological differentiation, higher tumor stage, and
presence of any of the following: microvascular invasion
(MVI), intrahepatic metastasis, tumor rupture or portal
venous invasion were significant risk factors for immediate
post-operative recurrence of HCC [3]. Despite remarkable
improvement in surgical techniques and perioperative
management, the long-term outcome after resection ofThis is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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operative recurrence.
The assessment of the impact factors for small hepato-
cellular carcinoma represents a hot-topic issue that
requires further investigation and clarifications. The
present study was performed to identify the risk factors
for recurrence and survival of SHCCs.
Methods
This study was conducted in accordance with a protocol
approved by the institutional review board of Zhongshan
Hospital, Fudan University.
All SHCC patients (1376) were confirmed from routing
diagnostic criteria from 3467 patients treated with liver re-
section for liver space-occupying masses (1376/3467, 40%)
in Liver Cancer Institution, Zhongshan Hospital between
2006 and 2008. Five hundred and thirteen patients with
complete clinicopathological and follow-up data from
1376 patients were chosen for analysis. Fifty-five patients
with multiple tumors were excluded from the study. In
all, 458 SHCC patients were reviewed to investigate the
prognostic factors of SHCC in our study.
The following clinicopathological and surgical variables
were evaluated for their influence on progression-free (PFS)
and overall survival (OS): age, gender, disease etiology,
alfa-fetoprotein (AFP) level, tumor capsule, border, histo-
logical differentiation, morphology subtype, fatty change,
tumor infiltrative lymphocytes (TIL) MVI, inflammatory
injury grade and fibrosis stage of surrounding liver.
Serologic presence of any hepatitis B antigen or antibody
was considered to be positive evidence of hepatitis B virus
(HBV). The serologic presence of hepatitis C antibody
was considered as evidence of positive for hepatitis C
virus (HCV). Tumor size was based on the largest dimen-
sion of the tumor recorded by surgeon. Tumor grade was
assessed using the scheme outlined by Edmondson and
Steiner and was recorded based on the highest grade in a
specimen [4]. Microvascular invasion (MVI) was defined
as presence of tumor emboli in a portal radicle vein, large
capsule vessel or in a vascular space lined by endothelial
cells [5]. TIL were evaluated by counting the number of
lymphocytes in tumor areas adjacent to surrounding liver
microscopically. The degree of fibrosis was assessed on
the basis of the Ishak score, and grades F5 and F6 were
considered cirrhosis [4].
Follow-up
Patients were followed up by the Liver Cancer institution,
every three months by tumor marker analysis (AFP)
and ultrasound or computed tomography at least every
6 months for more than two years. The last date of
follow-up is July 6th, 2012. Mean follow-up was 54
months (4~75 months). Patients who had tumor recur-
rence were treated with re-resection when possible orby transcatheter arterial chemoembolization, percutaneous
ethanol injection, radiofrequency ablation or radiotherapy.
Progression free survival (PFS) was defined as the number
of months from the date of surgery to the first docu-
mentation of disease recurrence or progression. Disease
progression or recurrence status was determined on the
basis of objective imaging according to RECIST criteria.
Disease-specific overall survival (OS) was defined as the
number of months from the date of surgery to the date of
the last follow-up visit or time of death attributed to HCC.
Statistical analysis
Statistical Analysis was performed using IBM SPSS soft-
ware (version 16.0, SPSS Ink). We performed analysis of
survival with Kaplan-Meier curves. Significant variables
were tested in multivariate analysis using Cox propor-
tional hazads regression model. Statistical significance was
considered reached when p-value was below 0.05. Pearson
X2 test was used for the assessment of variables associated
with MVI. Peri-operation deaths were included in the
analysis of overall survival results but excluded from the
analysis of progression-free survival. Relative Risk (RR)
and Odds Ratio (OR) were calculated using χ2 test.
Results
Clinicopathological characteristics
The clinicopathologic data of the patients cohort are sum-
marized in Table 1. There were 384 males and 74 females
with male to female ratio approximately 4.8:1. Mean age
at diagnosis was 52.7 (10~87) years. HBV was the etiologic
agent in 421 (91.9%) patients, four (0.9%) patients infected
with HCV, one (0.2%) patient co-infected with hepatitis
B and C, the other one (0.2%) patient co-infected with
hepatitis B and E. Thirty (6.6%) patients without virus
infection. Among the 446 patients with pre-operation
serum AFP level record, 147 (33.0%) patients had serum
AFP level ≥ 200 ug/ml. Of the 280 patients with post-
operation serum AFP level record, 178 (63.6%) patients
exhibited post-operation serum AFP level ≥ 20 ug/ml.
Of the 449 patients with capsule record, 249 (55.5%)
tumors were encapsulated, 200 (44.5%) tumors with
partial capsule. A total of 434 tumors had well-demarcated
border. Liver cirrhosis was presented in 411 (89.7%) cases.
Nine (2.0%) cases were observed with schistoma eggs
in the portal areas. MVI was identified in 83 (18.1%)
patients. MVI was observed at a magnification of 200×
with cluster tumor cells gathering in a vascular space
with/without smooth muscle wall, and mixed with blood
cells (Figure 1).
Impact factors of long-term survival
Among 458 patients, 102 (22.3%) patients experienced
HCC recurrence or de novo tumors. Eighty-four (18.3%)
patients died within 5 years follow-up, among which 50
Table 1 Clinicopathological characteristics of 458 patients
with single SHCC
Clinicopathological features Valuea




Pre-operation AFP value ≥200 ug/mla 147 (33.0%)
Post-operation AFP value ≥20 ug/mlb 178 (63.6%)
Virus infectionc















Well differentiated 14 (3.1%)
Moderately differentiated 345 (75.3%)














Large cell dyplastic change
Y 36 (7.9%)
N 422 (92.1%)
Table 1 Clinicopathological characteristics of 458 patients
with single SHCC (Continued)





aMissing data in 12 cases.
bMissing data in 178 cases.
cMissing data in 1 cases.
dMissing data in 9 cases.
eMissing data in 12 cases.
AFP a-fetoprotein, MVI microvascular invasion.
aValues are expressed as n(%) or median(range).
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OS durations were 53 and 54 months, respectively. The
5- year PFS and OS rate was 77.7% and 81.7%, respectively.
Univariate analysis suggested that SHCC patients with
MVI had shortened PFS and OS (p = 0.012, 0.028, respect-
ively) (Figure 2). Kaplan-Meier survival analyses revealed
that MVI was associated with poorer PFS and OS for
females (p < 0.001, PFS&OS, both), patients with G2 or
G3 histological differentiation (p = 0.017, 0.008, PFS&OS,
respectively), pre-operation serum AFP level ≥ 200ug/ml
(p = 0.022, 0.014, PFS& OS, respectively), or post-operation
serum AFP level ≥ 20 ug/ml (p = 0.014, 0.003, PFS&OS,
respectively), as well as patients with TIL ≥ 50/HPF in
tumor areas (p = 0.001, p = 0.006, PFS&OS, respectively)
(Table 2).
Impact factors of microvascular invasion
Pearson X2 analysis indicated that histological differenti-
ation (p = 0.009) was closely related with MVI. In well or
moderately differentiated tumors, 15.6% with MVI, com-
pared to 27.0% in poorly differentiated tumors. Increasing
tumor size was also associated with higher rates of MVI.
Discussion
Evidence had suggested that tumor size is one of the
most important prognostic factors of patients with hepa-
tocellular carcinoma (HCC) [6]. The latest Consensus on
Diagnosis and Treatment of Primary Liver Cancer in
China adopted 3 cm as the definition of small HCC [2].
Increasing research showed that when HCC is about
3 cm in size may be important as changes occur in DNA
stemline and biological characteristics, and HCC > 3 cm
exhibited a tendency towards more aggressive behavior
and may reach an important turning point for critical
transformation with a resultant change to a more infiltra-
tive behavior [7,8].
It is generally accepted that the incidence of HCC is
higher in men than in women. Gender was not an inde-
pendent prognostic factor for SHCC patients in our study,
however, MVI displayed survival differences in female
A B
C D
Figure 1 Mrophological features of MVI. Tumor thrombus were found in vessels of surrounding liver in A SHCC without capsule (HE ×100); B SHCC
with infiltrative lymphocytes ≥ 50/HPF (HE ×200); C SHCC with invasive border and incomplete capsule (HE ×100); D poorly differentiated SHCC (HE ×50).
p=0.012 p=0.028
A B
Figure 2 Cox Regression analysis of SHCC patients with MVI. 5 year cumulative survival of patients with MVI after hepatectomy, A PFS
(p = 0.012); B OS (p = 0.028).
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Table 2 Impact of MVI and following factors for SHCC
patients’ survival





Male 69 315 0.257 0.223
Female 14 60 0.002 0.000
Age(yr)
≥50 44 218 0.311 0.081
<50 39 157 0.028 0.095
Pre-operation AFP
value (ug/ml)
≥200 25 122 0.022 0.014
<200 55 244 0.370 0.330
Post-operation AFP
value (ug/ml)
≥20 34 144 0.021 0.003
<20 19 82 0.339 0.633
Cirrhosis
Y 75 336 0.023 0.056
N 8 39 0.747 0.174
Capsule
Y 39 211 0.798 0.810
N 41 159 0.008 0.006
Tumor border
Y 78 356 0.012 0.035
N 4 8 0.051 0.091
Tumor infiltrative
lymphocytes(/HPF)
≥50 10 74 0.001 0.006
<50 73 301 0.065 0.114
Tumor
differentiation
G1 2 12 0.752 0.752
G2&G3 81 363 0.008 0.017
p value1: p value of factors affecting patients’ PFS.
p value2: p value of factors affecting patients’ OS.
AFP a-fetoprotein, MVI microvascular invasion.
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showed that AFP had a positive correlation with gender.
Differences in several aspects of medical management
may contribute to the gender disparity in survival rates.
Underlying mechanism is still obscure and optimal
therapeutic regimens or hormonal mechanisms regard-
ing HCC development should be elucidated to improve
clinical outcomes [9].
AFP has served as a representative tumor marker of
HCC for more than 40 years. Liu et al. confirmed that
AFP levels were remarkably higher in patients with vas-
cular invasion (P < 0.001) [10]. High pre-operation andpost-operation AFP level has certain relationship with
long-term survival and MVI. While AFP level is positively
associated with tumor size, the larger tumor the higher
AFP, it is reasonable that AFP level failed to show a prog-
nostic value for survival of SHCC patients.
Microvascular invasion is a histological feature of hepato-
cellular carcinoma related to aggressive biological behavior.
HCC is characterized by a tendency for vascular invasion.
During the past decades, many studies have addressed
the prognostic significance of MVI in HCC, either as a
primary or secondary object. Nevertheless, the prognostic
significance of MVI remains controversial, and there is
a significant interobserver and intraobserver variability
in the assessment of MVI. Junichi et al claimed that
microvascular invasion does not affect survival of SHCC
(up to 2 cm) [11], others with opposite opinion that
microscopic vascular invasion was an independent factor
for SHCC (up to 3 cm) [12]. Our findings indicate that
MVI has an adverse impact on long-term survival in
SHCC patients. Presence of MVI led to a significant
decrease in PFS and OS at 5 years. Combined our results
with other four studies included in Manuel Rodrıguez-
Peralvarez et al meta-analysis (n = 1959), the RR of
MVI to PFS survival was 1.34 (95% CI =1.24-1.51) [5].
An international consensus delineating what is meant by
MVI in HCC could provide a more consistent evaluation
and, therefore, a more reliable prediction of prognosis
and a better understanding of the pathophysiology of
HCC angioinvasion.
Because microvascular invasion is a histopathologic
diagnosis, it cannot be made prior to the resection of
the tumor. Given the fact that MVI has a significant
impact on recurrence and survival after hepatectomy,
preoperative means of assessing the probability of MVI
are needed. Increasing tumor size and AFP level were
also recorded to be associated with higher rates of MVI
[13,14] in others research. In current study, we found
that tumor grade is a strong predictor of MVI. It’s well-
proved that histological grade was an important prog-
nostic factor for survival of HCC patients [15]. It has a
strong relationship with MVI but has no statistically
significance on survival, since most of the patients were
moderately differentiated in our study. It indicated that
SHCC may be not an early-stage of HCC, it certainly
represents an earlier lesion. A significant correlation
between infiltrative tumor margin in preoperative CT
and MVI was claimed, indicating tumor margin may serve
as a radiological sign in prediction of MVI in HCC
patients [16].
Tumor gross features including cirrhosis, capsule and
border failed to show prognostic impact on patients’ sur-
vival. Liver resection in the presence of compensated
liver cirrhosis is feasible but associated with a signifi-
cantly unfavored prognosis for overall and progression-
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cirrhosis are important methods to improve the survival
of HCC patients [17,18].
None of morphological features of surrounding liver
correlated with MVI and patients’ survival, including
peritumor large cell dysplastic foci (LCD), fatty change
of hepatocytes. LCD was originally considered a precursor
lesion of HCC and, accordingly, was referred to as dys-
plastic. Based on genetic and animal tests, Ferrell thought
that LCD were pathogenetically linked to and associated
with HCC but do not represent a direct precursor of HCC
[19]. Tumor fatty change was more easily observed in
patients with well differentiation (Grade I-II), a signifi-
cant proportion of small (<2 cm) or “early” HCCs that
are only vaguely nodular have been observed to have
diffuse fatty change [20].
HCC is an example of inflammation-related cancer and
represents a paradigm of the relation occurring between
tumor microenvironment and tumor development. Stromal
cells in tumor microenvironment secrete cytokines and
proteins that promote angiogenesis, metastasis may
contribute to MVI.
The prognosis of HCC patients remains unsatisfactory
although it has been improved much in the past decades.
For SHCC patients, resection is considered the most
effective treatment. However, recurrence is the leading
cause of death during the initial 5-year period after in-
tensive radical resection. High possibility of intrahepatic
recurrence remains one major obstacle for further
improving the survival and prognosis of SHCC patients
after curative resection. As MVI was a pivotal impact
factor for SHCC, the detection and prevention for MVI
will be a target for the therapy of SHCC patients. We will
dedicated in developing the model for prediction of
HCC patients’ survival and exploring measures to prevent
recurrence or metastasis. For those patients with high
risk factors of recurrence, intensive follow-up with
serum AFP and radiology is one of the best methods to
be recommended.Conclusions
In conclusion, the present study confirmed that micro-
vascular invasion has adverse effect on single small he-
patocellular carcinoma patients’ survival and more easily
discovered in worse differentiated and large tumor patients,
we wish to establish a model which can predict and im-
prove the survival of HCC patients.Consent
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